12
1 Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. Chapter 19 Hematologic Products

Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

Embed Size (px)

Citation preview

Page 1: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

1Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Chapter 19Chapter 19

Hematologic Products

Page 2: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

2Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Chapter 19

Lesson 19.1

Page 3: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

3Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Learning ObjectivesLearning Objectives

• Describe the influence of anticoagulants on blood clotting

• Develop a teaching plan for patients taking anticoagulants on a long-term basis

• Identify drugs that act in the formation, repair, or function of red blood cells

• Identify at least three adverse reactions associated with hematologic products.

Page 4: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

4Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

AnticoagulantsAnticoagulants

Two Categories– Coumarin and indandione derivatives

• – Limit the formation of blood coagulation factors II, VII, IX, and X in the liver by interfering with vitamin K

– Heparin sodium• – Increases the action of antithrombin III

(heparin cofactor) on several other coagulation factors to slow new clot development

Page 5: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

5Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Anticoagulants (cont.)Anticoagulants (cont.)

Action and Uses• Prevent new thrombus formation• Stop existing thrombi from growing in size• Prophylactic: postsurgery involving the heart or

circulatory system• Patients with heart valve disease, some

dysrhythmias, and receiving hemodialysis• Patients on prolonged bed rest or with a history

of thrombus formation

Page 6: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

6Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Anticoagulants (cont.)Anticoagulants (cont.)

Adverse Reactions• Warfarin (Coumadin): alopecia, rash, urticaria,

cramping, diarrhea, intestinal obstruction, nausea, paralytic ileus, vomiting, excessive uterine bleeding, hemorrhage, leukopenia, fever

• Heparin sodium: hypertension, headache, hematoma, conjunctivitis, tearing of eyes, rhinitis, hemorrhage, thrombocytopenia, dyspnea, chills, fevers, alopecia, persistent or prolonged erection, hypersensitivity

Page 7: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

7Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Anticoagulants (cont.)Anticoagulants (cont.)

Drug Interactions

Nursing Implications and Patient Teaching• Calculation procedure of heparin critical• Monitoring blood values

– Coumadin = prothrombin time (PT); therapeutic is 1.5 to 2.5 × normal or an INR of 2.0 to 3.0

– Heparin = activated partial thromboplastin time (aPPT); therapeutic is 2.5 to 3 × the control value

Page 8: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

8Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Anticoagulants (cont.)Anticoagulants (cont.)

• Nursing Process– Assessment– Diagnosis

– Planning

– Implementation

– Evaluation

• Patient and Family Teaching

Page 9: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

9Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Protamine SulfateProtamine Sulfate

Action• Strong, alkaline protein that neutralizes effects of

heparin• Results immediate, last 2 hours or more

Uses• Treatment of heparin overdosage• After surgical procedure where heparin was used

Adverse Reactions

Page 10: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

10Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Thrombolytic AgentsThrombolytic Agents

Action• Convert plasminogen to the enzyme plasmin,

which breaks down fibrin clots, fibrinogen, and other plasma proteins

Uses• Acute myocardial infarctions• Acute pulmonary emboli• Acute ischemic stroke• Acute arterial occlusion

Page 11: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

11Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Antiplatelet AgentsAntiplatelet Agents

Action• Inhibit platelet aggregation (clumping)• Reduce thrombus formation

Uses• Salicylic acid (aspirin)

– Reduces incidence of myocardial-infarction-related deaths in men over 50

– Drug of choice in ischemic stroke

Page 12: Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc. 1 Chapter 19 Hematologic Products

12Elsevier items and derived items © 2010, 2006, 2003, 2000 by Mosby, an imprint of Elsevier Inc.

Antiplatelet Agents (cont.)Antiplatelet Agents (cont.)

Uses (cont.)• Dipyridamole (Persantine), ticlopidine (Ticlid),

clopidogrel (Plavix)– Myocardial prophylaxis for men– Adjunctive therapy with thrombolytics to prevent an

infarction or stroke

• Abciximab (ReoPro), anagrelide (Agrylin)– During cardiac catheterization and cardiac

procedures